Good evening and welcome to Markets Desk, your close-of-day read on what's moving markets and why.
In the lung cancer space, two headlines pulled in opposite directions today. HUTCHMED reported strong Phase Three results for its savolitinib and osimertinib combination, showing meaningful progression-free and overall survival benefits in EGFR-mutant non-small cell lung cancer patients. That's a genuine clinical win with commercial implications for both HUTCHMED and its partner AstraZeneca. Speaking of AstraZeneca, the British pharma giant separately announced it is halting its eVOLVE-Lung-oh-two trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer, following a recommendation from the independent data monitoring committee. A discontinuation at Phase Three is never a clean story, and investors will be watching for clarity on what that pipeline gap means for AstraZeneca's oncology ambitions.
Shifting to semiconductors, Micron has clawed back sharply from its late July lows, with shares recovering from seven hundred thirty nine dollars to nearly nine hundred eighty dollars by mid-August. The question now circling analyst desks is whether management will authorize a stock split before the end of two thousand twenty six, a move that could broaden retail participation as the AI memory cycle continues to build momentum beneath the surface.
That's the tape. Markets Desk, signing off the floor.
